Lernicor, 20 mg 28 pcs.

Arterial hypertension degree 1-2.

Indications

Arterial hypertension grade 1–2.

Pharmacological effect

Pharmacological action – hypotensive.

Special instructions

Particular caution should be exercised when prescribing lercanidipine to patients with sick sinus syndrome (without a pacemaker).

Active ingredient

Lercanidipine

Composition

Film-coated tablets
1 table
active substance:
lercanidipine hydrochloride
10/20 mg
excipients:

MCC – 39/78 mg;

lactose monohydrate – 30/60 mg;

sodium carboxymethyl starch (sodium starch glycolate) – 15.5/31 mg;

povidone K30 – 4.5/9 mg;

magnesium stearate – 1/2 mg
film coating (dosage 10 mg):

Opadry II 85F38107 yellow (polyvinyl alcohol – 1.2 mg, titanium dioxide – 0.6684 mg, macrogol (polyethylene glycol) – 0.606 mg, talc – 0.444 mg, aluminum varnish based on quinoline yellow dye – 0.0807 mg, iron oxide red – 0.0009 mg)
film coating (dosage 20 mg):

Opadry II 85F34555 pink (polyvinyl alcohol – 2.4 mg, titanium dioxide – 1.4046 mg, macrogol (polyethylene glycol) – 1.212 mg, talc – 0.888 mg, aluminum varnish based on the “Charming Red” dye – 0.0348 mg, aluminum varnish based on the “Sunset Yellow” dye – 0.0336 mg, aluminum varnish based on azorubine dye – 0.027 mg)

Contraindications

Hypersensitivity to lercanidipine, other dihydropyridine derivatives or any component of the drug;
untreated chronic heart failure;
unstable angina;
obstruction of the outflow tract of the left ventricle;
period within 1 month after myocardial infarction;
severe liver failure;
severe renal failure (creatinine Cl less than 30 ml/min);
simultaneous use with potent inhibitors of CYP3A4 (ketoconazole, itraconazole, erythromycin, ritonavir, troleandomycin);
simultaneous use with cyclosporine;
simultaneous use with grapefruit juice;
lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome;
use in women of childbearing age who do not use reliable methods of contraception;
pregnancy;
breastfeeding period;
age under 18 years (efficacy and safety have not been studied).
With caution: renal failure (creatinine Cl more than 30 ml/min) and/or mild to moderate liver failure; old age; sick sinus syndrome (without pacemaker); coronary heart disease; left ventricular dysfunction.

Side Effects

Possible adverse reactions are listed below in descending frequency of occurrence: often (1/100); uncommon (1/1000); rarely (1/10000); very rare (<1/10000), including isolated reports.

Interaction

Lercanidipine can be used simultaneously with beta-blockers, diuretics, and ACE inhibitors.

Overdose

Symptoms: peripheral vasodilation with a pronounced decrease in blood pressure and reflex tachycardia (presumably in case of an overdose of lercanidipine, symptoms similar to those of an overdose of other dihydropyridine derivatives will be observed).

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years.

Manufacturer

Obolenskoye FP JSC, Russia